CD8A and neoplasm: Shin-Wha Lee et al. found that a therapy approach using CD8α+ DCs, induced from HSCs, similar to the population of human CD141+ DCs, not only promotes tumor regression but also contributes to a higher level of immune-stimulating cells such as CD4+, CD8+, and CD11c+, as well as a lower level of the immunosuppressive cytokine IL-10 at lower therapeutic doses, compared to moDC therapy in a mouse model [102].